The non-enumerable described retrovirus integrase inhibitors are not a lure, as evidenced by ten years of clinical experience.
Two retrovirus integrase inhibitors have been discovered on the c-erb proto-oncogene test in 1989, acriflavine and hydroxymethylellipticine. A ten-year follow-up of their applications to individual treatments of AIDS patients has provided evidence of their HIV-1 (even AZT-resistant) virostatic efficacy, as of their possible clinical use without toxicity. Hundreds of HIV-1 integrase inhibitors have recently been discovered with an in vitro test. The clinical effect of vitamin B12, which belongs to them, has already been observed in patients with one-year follow-up. A positive coordination of return to this Eden of HIV-1-AIDS complex pharmacology must be organized at the highest scientific, and not at the politico-administrative level.
Mathé
G
G
Institut de Cancérologie et d'Immunologie, Issy-les-Moulineaux, France.
D015658:HIV Infections / Q000188:drug therapy*; D019428:HIV Integrase Inhibitors / Q000627:therapeutic use*; D015497:HIV-1; D006801:Humans; D000090063:Proto-Oncogene Mas
D019428:HIV Integrase Inhibitors; C000715470:MAS1 protein, human; D000090063:Proto-Oncogene Mas